尽管有新的Attruby数据，BridgeBio仍下跌

2026-05-12 03:11

BridgeBio Pharma (BBIO) is down ~4% in Monday trading despite releasing phase 3 heart failure data for Attruby (acoramidis).
Results from the ATTRibute-CM study found that the drug led to consistent and clinically meaningful benefits across the transthyretin amyloid cardiomyopathy (ATTR-CM) disease spectrum.
The data also showed modifying effects across clinical outcomes, biomarkers, and functional capacity.
In an oral presentation, it was explained that with Attruby, there was an association between the treatment-related increase in serum transthyretin (sTTR) and a significant reduction of sTTR variability over time. That reduction is consistent with a decline in all-cause mortality.

More on BridgeBio Pharma